; and (II) if the termination occurs on or after January 30 of a plan year, as of the day after the end of the succeeding plan year. (iii) Effectiveness of termination Any termination under this subparagraph shall not affect discounts for insulin drugs of the manufacturer that are due under the agreement before the effective date of its termination. (iv) Notice to third party The Secretary shall provide notice of such termination to a third party with a contract under subsection (d)(3) within not less than 30 days before the effective date of such termination. (c) Duties described The duties described in this subsection are the following: (1) Administration of program Administering the program, including— (A) the determination of the amount of the Medicaid price of an insulin drug of a manufacturer for applicable individuals in each State; (B) except as provided in subparagraph (C), the establishment of procedures under which Medicaid prices are provided to applicable individuals at pharmacies or by mail order service at the point-of-sale of an insulin drug; (C) in the case where, during the period beginning on January 1, 2022, and ending on December 31, 2022, it is not practicable to provide such Medicaid prices at the point-of-sale (as described in subparagraph (B)), the establishment of procedures to provide such Medicaid prices as soon as practicable after the point-of-sale; (D) the establishment of procedures to ensure that, not later than the applicable number of calendar days after the dispensing of an insulin drug by a pharmacy or mail order service, the pharmacy or mail order service is reimbursed for an amount equal to the difference between— (i) the negotiated price of the insulin drug; and (ii) the Medicaid price of the insulin drug